Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1018 results about "Diagnostic agent" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Diagnostic Agent. Diagnostic agents are used to diagnose certain conditions. X-ray dyes and radioactive isotopes are substances injected into the body in order to highlight certain areas during X-rays, MRI or CT Scans. Learn more about diagnostic agents from our experts.
Oligonucleotide analogues
Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.
Owner:EXIQON AS
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
InactiveUS6923988B2Rapid dissolvableMore solubilizedAntibacterial agentsOrganic active ingredientsDiagnostic agentTG - Triglyceride
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.
Owner:LIPOCINE
Multivalent immunoglobulin-based bioactive assemblies
ActiveUS7527787B2Efficacious for arrestingInhibition formationPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseDiagnostic agent
Owner:IBC PHARMACEUTICALS INC
Intra-aortic renal drug delivery catheter
InactiveUS7122019B1Reduce the amount requiredDecreased blood flowBalloon catheterMulti-lumen catheterContinuous perfusionBoth kidneys
A catheter for delivering a therapeutic or diagnostic agent to a branch blood vessel of a major blood vessel, generally comprising an elongated shaft having at least one lumen in fluid communication with an agent delivery port in a distal section of the shaft, an expandable tubular member on the distal section of the shaft, and a radially expandable member on the tubular member. The tubular member is configured to extend within the blood vessel up-stream and down-stream of a branch vessel, and has an interior passageway which is radially expandable within the blood vessel to separate blood flow through the blood vessel into an outer blood flow stream exterior to the tubular member and an inner blood flow stream within the interior passageway of the tubular member. The radially expandable member is located down-stream of the shaft agent delivery port, and has an expanded configuration with an outer diameter larger than an outer diameter of the tubular member. The expanded radially expandable member is configured to decrease the blood flow in the outer blood flow stream down-stream of the branch vessel. The catheter provides for delivery of an agent to a branch vessel of a major vessel, and continuous perfusion of the major blood vessel. Another aspect of the invention is directed to methods of delivering a therapeutic or diagnostic agent to one or both kidney's of a patient.
Owner:ANGIODYNAMICS INC
Anti-TIM-3 antibody
The present invention provides an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.
Owner:KYUSHU UNIV +1
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
InactiveUS20060034937A1Good chemical stabilityPromote absorptionGranular deliveryMicrocapsulesDiagnostic agentMedicine
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.
Owner:LIPOCINE
Delivery of Nanoparticles and/or Agents to Cells
InactiveUS20080213377A1Extended circulation timeReduce degradationPowder deliverySugar derivativesDiagnostic agentNanoparticle
The present invention provides systems, methods, and compositions for targeted delivery of nanoparticles and / or agents to tissues, cells, and / or subcellular locales. In general, compositions comprise a nanoparticle (e.g. quantum dot, polymeric particle, etc.), at least one modulating entity (such as a targeting moiety, transfection reagent, protective entity, etc.), and at least one agent to be delivered (e.g. therapeutic, prophylactic, and / or diagnostic agent). The present invention provides methods of making and using nanoparticle entities in accordance with the present invention.
Owner:MASSACHUSETTS INST OF TECH
Multivalent immunoglobulin-based bioactive assemblies
ActiveUS20070140966A1Prevent further clot formationHigh affinityPeptide/protein ingredientsAntibody mimetics/scaffoldsDiagnostic agentAutoimmune condition
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and / or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and / or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and / or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and / or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and / or diagnostic agents.
Owner:IBC PHARMACEUTICALS INC
Intra-aortic renal drug delivery catheter
InactiveUS7329236B2Avoid and limit detrimental effectIncrease concentrationBalloon catheterMulti-lumen catheterDiagnostic agentGuide tube
A catheter for delivering a therapeutic or diagnostic agent to a branch blond vessel of a major blood vessel comprises an elongated shaft having at least one lumen in fluid communication with an agent delivery port in a distal section of the shaft, an expandable tubular member on the distal section of the shaft, and a radially expandable member on the tubular member. The tubular member is configured to extend within the blood vessel up-stream and down-stream of a branch vessel, and has an interior passageway which is radially expandable within the blood vessel to separate blood flow through the blood vessel into an outer blood flow stream exterior to the tubular member and an inner blood flow stream within the interior passageway of the tubular member.
Owner:ANGIODYNAMICS INC
Production and use of novel peptide-based agents for use with bi-specific antibodies
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.
Owner:IMMUNOMEDICS INC
Immunosuppression modulating compounds
The present invention provides immunosuppression compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and / or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
Owner:AURIGENE DISCOVERY TECH
Methods and devices for retrieval of a medical agent from a physiological efferent fluid collection site
Methods and devices for selectively removing an agent from a physiological efferent fluid collection site are provided. A feature of the invention is that a non-occlusive aspiration device is employed to selectively remove the target agent from the site only when the target agent is present in the site. Also provided are systems and kits for performing the subject methods. The subject invention finds use in a variety of different applications, including the selective removal of both therapeutic and diagnostic agents from a variety of different physiological sites.
Owner:CATHAROS MEDICAL SYST
Parenteral delivery systems
Hypertonic sugar compositions administered by other than ingestion and swallowing or intravascular injection, such as by intranasal spray or drops, intraocular drops or ointment, oral spray, intraotic spray or drops, lozenges, chewable tablet, chewing gum, or gargle, pulmonary inhalation, vaginal or rectal suppositories, or transdermal creams, ointments, lotions, or patches, are effective to open the blood-brain barrier to permit entry into the central nervous system of a co-administered chemical compound, such as a nutrient or a therapeutic or diagnostic agent. In this way, the compositions and methods of the invention increase the therapeutic or diagnostic efficacy of such chemical compounds.
Owner:NAITO ALBERT T
Diagnostics And Monitoring Services In A Mobile Network For A Mobile Device
InactiveUS20070207800A1Radio/inductive link selection arrangementsData switching networksPagerMobile electronics
The present invention makes it possible to obtain debug- and other diagnostic information from mobile electronic devices in a system operator network. A Log Management object provides support for logging diagnostic data. A log file is employed to collect information on various device features for which tracing or debugging is turned on in a mobile electronic device such as, for example, a mobile handset, cellular phone, a personal digital assistant, a pager and a personal computer. It is also used to selectively collect information on specific events that are monitored, device specific data being collected, and network performance data, among other items. The diagnostic agent in the mobile device is a client side application that may run on the mobile device when required, or continuously as a monitoring application, and which manages and collects tracing information wirelessly to a server using a cellular data network. A diagnostic client may also be downloaded and executed to collect diagnostic data from applications, for example. Traps may also be set and data collected from them. The Log file may be retrieved from the server side in pull or push mode.
Owner:QUALCOMM INC
Apparatus delivery in an intervertebral disc
ActiveUS20050004578A1Convenient and reliable and accurateConvenient guidanceInternal osteosythesisCannulasDiagnostic agentIntervertebral disc
The present invention relates generally to intervertebral disc devices and methods and instrumentation for intervertebral disc procedures. Methods include performing procedures such as implant delivery, tissue manipulation, tissue diagnostics, and therapeutic and diagnostic agent delivery at selected locations within intervertebral discs.
Owner:INTRINSIC THERAPEUTICS
Intra-aortic renal drug delivery catheter
InactiveUS7481803B2Reduce the amount requiredDecreased blood flowStentsBalloon catheterDiagnostic agentBlood vessel
A catheter for delivering a therapeutic or diagnostic agent to a branch blood vessel of a major blood vessel, generally comprising an elongated shaft having at least one lumen in fluid communication with an agent delivery port in a distal section of the shaft, an expandable tubular member on the distal section of the shaft, and a radially expandable member on the tubular member. The tubular member is configured to extend within the blood vessel up-stream and down-stream of a branch vessel, and has an interior passageway which is radially expandable within the blood vessel to separate blood flow through the blood vessel into an outer blood flow stream exterior to the tubular member and an inner blood flow stream within the interior passageway of the tubular member.
Owner:ANGIODYNAMICS INC
Enhanced transport using membrane disruptive agents
Owner:UNIV OF WASHINGTON +1
Enhanced transport using membrane disruptive agents
InactiveUS7737108B1Prevent uptakePrevent clearanceBiocidePeptide/protein ingredientsMetaboliteCell layer
Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and / or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes (at physiologic pH, but can become active toward cell membranes if the environment is acidified below ca. pH 6.8), coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and / or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and / or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and / or electrophereis can also be used with the disrupting agents.
Owner:UNIV OF WASHINGTON
Methods of synthesis and use of chemospheres
InactiveUS20110104052A1Prevents immunoclearanceExtended half-lifePowder deliveryBiocideDiagnostic agentComputed tomography
The present invention provides, in general, compositions comprising a hydrogel and an agent, for example a therapeutic agent or an imaging agent, for locoregional delivery. In certain preferred embodiments of the invention, the hydrogel compositions are detectable by Magnetic Responance and CT Scan and are used for locoregional delivery of therapeutic agents, for example chemotherapeutic agents. The invention also features polymer matrix compositions comprising nanoparticles that can be loaded after polymerization with bioactive agents, for example a diagnostic agent or therapeutic agent.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
InactiveUS7074405B1Increased toxicityLow toxicityHybrid immunoglobulinsInorganic boron active ingredientsEpitopeDiagnostic agent
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
Owner:IMMUNOMEDICS INC
Intra-dermal delivery of biologically active agents
InactiveUS20050163711A1Rapid uptakeFast shippingMetabolism disorderDigestive systemLymphatic vesselDiagnostic agent
The present invention relates to methods and devices for delivering one or more biologically active agents, particularly a diagnostic agent to the intradermal compartment of a subject's skin. The present invention provides an improved method of delivery of biologically active agents in that it provides among other benefits, rapid uptake into the local lymphatics, improved targeting to a particular tissue, improved bioavailability, improved tissue bioavailability, improved tissue specific kinetics, improved deposition of a pre-selected volume of the agent to be administered, and rapid biological and pharmacodynamics and biological and pharmacokinetics. This invention provides methods for rapid transport of agents through lymphatic vasculature accessed by intradermal delivery of the agent. Methods of the invention are particularly useful for delivery of diagnostic agents.
Owner:BECTON DICKINSON & CO
Anti-tim-3 antibody
ActiveUS20140044728A1High activityPeptide/protein ingredientsAntipyreticExtracellularDiagnostic agent
Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.
Owner:KYOWA HAKKO KIRIN CO LTD
Bi-specific antibodies for pre-targeting diagnosis and therapy
InactiveUS7052872B1Increased toxicityLow toxicityIn-vivo radioactive preparationsSugar derivativesEpitopeDiagnostic agent
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
Owner:IMMUNOMEDICS INC
Therapeutic using a bispecific antibody
Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.
Owner:IMMUNOMEDICS INC
Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
ActiveUS20070264265A1Avoid infectionReduce eliminateOrganic active ingredientsAntiviralsDiagnostic agentBinding site
The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4 / D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent.
Owner:IMMUNOMEDICS INC
Liquid Transfer Device for Medical Dispensing Containers
Liquid transfer device to be used to transfer a liquid into or from a dispensing container, particularly a medical dispensing container like a vial for diagnostic agents and kit comprising a vial, a syringe and a device of the aforementioned type. The transfer device comprises a valve which substantially limits the gaseous exchange between the inside of a vial and the external ambient, when the device is connected to the vial in steady state conditions.
Owner:BRACCO RES USA
Intra-aortic renal drug delivery catheter
InactiveUS20060189960A1Reduce the amount requiredDecreased blood flowBalloon catheterMulti-lumen catheterDiagnostic agentBlood vessel
A catheter for delivering a therapeutic or diagnostic agent to a branch blond vessel of a major blood vessel comprises an elongated shaft having at least one lumen in fluid communication with an agent delivery port in a distal section of the shaft, an expandable tubular member on the distal section of the shaft, and a radially expandable member on the tubular member. The tubular member is configured to extend within the blood vessel up-stream and down-stream of a branch vessel, and has an interior passageway which is radially expandable within the blood vessel to separate blood flow through the blood vessel into an outer blood flow stream exterior to the tubular member and an inner blood flow stream within the interior passageway of the tubular member.
Owner:ANGIODYNAMICS INC
Compositions for delivery of therapeutics and other materials
InactiveUS20080015263A1Easy to introduceKind be easilyBiocideIn-vivo radioactive preparationsDiagnostic agentBinding domain
This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion.
Owner:PHARMAIN CORP
Methods and devices for retrieval of a medical agent from a physiological efferent fluid collection site
Methods and devices for selectively removing an agent from a physiological efferent fluid collection site are provided. A feature of the invention is that a non-occlusive aspiration device is employed to selectively remove the target agent from the site only when the target agent is present in the site. Also provided are systems and kits for performing the subject methods. The subject invention finds use in a variety of different applications, including the selective removal of both therapeutic and diagnostic agents from a variety of different physiological sites.
Owner:CATHAROS MEDICAL SYST
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
InactiveUS20090074859A1Dissolve fastReduce deliveryAntibacterial agentsPowder deliveryDiagnostic agentTG - Triglyceride
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.
Owner:LIPOCINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com